2025년도 제2차 국가신약개발사업 발표평가 대상과제 공지

1

발표평가 대상과제

RFP(지원분야)

발표평가 대상과제-과제번호

(1내역)

신약 기반 확충 연구

유효물질단계

(24개)

RS-2025-25444468

RS-2025-25446405

RS-2025-25446616

RS-2025-25449569

RS-2025-25450045

RS-2025-25450321

RS-2025-25452008

RS-2025-25452139

RS-2025-25452986

RS-2025-25453059

RS-2025-25453250

RS-2025-25454753

RS-2025-25454766

RS-2025-25454812

RS-2025-25454817

RS-2025-25454892

RS-2025-25455032

RS-2025-25455041

RS-2025-25455100

RS-2025-25455104

RS-2025-25455335

RS-2025-25455439

RS-2025-25455628

RS-2025-25455859

선도물질단계

(29개)

RS-2025-25444327

RS-2025-25444336

RS-2025-25444375

RS-2025-25444455

RS-2025-25446147

RS-2025-25446153

RS-2025-25446605

RS-2025-25446859

RS-2025-25447260

RS-2025-25447926

RS-2025-25450700

RS-2025-25451065

RS-2025-25451838

RS-2025-25453299

RS-2025-25453899

RS-2025-25454256

RS-2025-25454741

RS-2025-25454801

RS-2025-25454886

RS-2025-25454972

RS-2025-25455070

RS-2025-25455130

RS-2025-25455240

RS-2025-25455301

RS-2025-25455308

RS-2025-25455324

RS-2025-25455402

RS-2025-25455457

RS-2025-25455843

(2내역)

신약 R&D 생태계 구축 연구

후보물질단계

(35개)

RS-2025-25444331

RS-2025-25444382

RS-2025-25444385

RS-2025-25444397

RS-2025-25444435

RS-2025-25444576

RS-2025-25445446

RS-2025-25446266

RS-2025-25447099

RS-2025-25447520

RS-2025-25448962

RS-2025-25449417

RS-2025-25449916

RS-2025-25450298

RS-2025-25450363

RS-2025-25450417

RS-2025-25451782

RS-2025-25451822

RS-2025-25452009

RS-2025-25452684

RS-2025-25453248

RS-2025-25453249

RS-2025-25453255

RS-2025-25453439

RS-2025-25454767

RS-2025-25454797

RS-2025-25454912

RS-2025-25454944

RS-2025-25454985

RS-2025-25454990

RS-2025-25455016

RS-2025-25455145

RS-2025-25455150

RS-2025-25455548

RS-2025-25455658

비임상단계

(24개)

RS-2025-25444387

RS-2025-25444421

RS-2025-25444670

RS-2025-25444945

RS-2025-25448300

RS-2025-25449690

RS-2025-25450730

RS-2025-25451385

RS-2025-25453205

RS-2025-25453791

RS-2025-25454561

RS-2025-25454748

RS-2025-25454770

RS-2025-25454784

RS-2025-25454943

RS-2025-25454959

RS-2025-25454976

RS-2025-25455086

RS-2025-25455096

RS-2025-25455195

RS-2025-25455212

RS-2025-25455321

RS-2025-25455442

RS-2025-25455606

(3내역)

신약 임상개발

임상단계

(임상1상, 임상2상)

(18개)

RS-2025-25444394

RS-2025-25446221

RS-2025-25446915

RS-2025-25450297

RS-2025-25450705

RS-2025-25451121

RS-2025-25452011

RS-2025-25454729

RS-2025-25454824

RS-2025-25455081

RS-2025-25444330

RS-2025-25444664

RS-2025-25452999

RS-2025-25453251

RS-2025-25454100

RS-2025-25454560

RS-2025-25454580

RS-2025-25454827

2

발표평가 안내

3

평가 관련 문의처

이메일

연락처

kddf_pm@kddf.org

02-6379-3083

4

참고사항